Works Cited
- Back to Course Home
- Participation Instructions
- Review the course material online or in print.
- Complete the course evaluation.
- Review your Transcript to view and print your Certificate of Completion. Your date of completion will be the date (Pacific Time) the course was electronically submitted for credit, with no exceptions. Partial credit is not available.
1. Ramachandraiah CT, Subramaniam N, Tancer M. The story of antipsychotics: Past and present. Indian J Psychiatry. 2009;51(4):324-326.
2. National Institute of Mental Health. Mental health medications. Available at https://www.nimh.nih.gov/health/topics/mental-health-medications/index.shtml#part_149866. Last accessed July 27, 2026.
3. Clinical Pharmacology powered by Clinical Key. Elsevier Inc.; 2026. Available at https://www.elsevier.com/solutions/clinical-pharmacology. Last accessed August 10, 2026.
4. National Institute of Mental Health. Schizophrenia. Available at https://www.nimh.nih.gov/health/statistics/schizophrenia.shtml#part_154880. Last accessed July 27, 2026.
5. Canadian Mental Health Association. Fast Facts about Mental Illness. Available at https://cmha.ca/fast-facts-about-mental-illness. Last accessed July 27, 2026.
6. Mayo Clinic. Understanding the 3 Symptom Domains of Schizophrenia – Positive, Negative, and Cognitive Symptoms. Available at https://mcpress.mayoclinic.org/schizophrenia/understanding-the-3-symptom-domains-of-schizophrenia-positive-negative-and-cognitive-symptoms/. Last accessed July 27, 2026.
7. Noel JM; American Society of Health-System Pharmacists. ASHP therapeutic position statement on the use of second-generation antipsychotic medications in the treatment of adults with psychotic disorders. Am J Health Syst Pharm. 2007;64(8):863-876.
8. Leo RJ, Regno PD. Atypical antipsychotic use in the treatment of psychosis in primary care. Prim Care Companion J Clin Psychiatry. 2000;2(6):194-204.
9. Hill SK, Bishop JR, Palumbo D, Sweeney JA. Effect of second-generation antipsychotics on cognition: current issues and future challenges. Expert Rev Neurother. 2010;10(1):43-57.
10. National Institute for Health Care Excellence. Psychosis and Schizophrenia in Adults: The NICE Guideline on Treatment and Management. Available at https://www.nice.org.uk/guidance/cg178/evidence/full-guideline-490503565. Last accessed July 27, 2026.
11. National Institute of Mental Health. Bipolar Disorder. Available at https://www.nimh.nih.gov/health/topics/bipolar-disorder/index.shtml. Last accessed July 27, 2026.
12. National Institute of Mental Health. Prevalence of Bipolar Disorder Among Adults. Available at https://www.nimh.nih.gov/health/statistics/bipolar-disorder.shtml. Last accessed July 27, 2026.
13. Mayo Clinic. Bipolar Disorder. Available at https://www.mayoclinic.org/diseases-conditions/bipolar-disorder/symptoms-causes/syc-20355955. Last accessed July 27, 2026.
14. National Institute for Health and Care Excellence. Bipolar Disorder: Assessment and Management. Available at https://www.nice.org.uk/guidance/cg185/resources/bipolar-disorder-assessment-and-management-35109814379461. Last accessed July 27, 2026.
15. American Psychiatric Association. Treating Bipolar Disorder: A Quick Reference Guide. Available at https://psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/guidelines/bipolar-guide.pdf. Last accessed August 10, 2026.
17. Guzman F. First-Generation Antipsychotics: An Introduction. Available at https://psychopharmacologyinstitute.com/publication/first-generation-antipsychotics-an-introduction-2110. Last accessed July 27, 2026.
18. Reynolds GP. Receptor mechanisms of antipsychotic drug action in bipolar disorder: focus on asenapine. Ther Adv Psychopharmacol. 2011;1(6):197-204.
19. Johns Hopkins Medicine. Antipsychotics. Available at https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_Diabetes_Guide/547011/all/Antipsychotics#d196712413e3. Last accessed July 27, 2026.
20. Silvia RJ, Dufresne RL, Ellison JC. Schizophrenia. In: Zeind CS, Carvalho MG, Cheng JWM, et al. (eds). Applied Therapeutics. 12th ed. Philadelphia, PA: Wolters Kluwer; 2024.
21. Kapur S, Remington G. Serotonin-dopamine interaction and its relevance to schizophrenia. Am J Psychiatry. 1996;153(4):466-476.
22. National Alliance on Mental Illness. Schizoaffective Disorder. Available at https://www.nami.org/About-Mental-Illness/Mental-Health-Conditions/Schizoaffective-Disorder. Last accessed August 10, 2026.
23. Mucci F, Arone A, Gurrieri R, et al. Third-generation antipsychotics: the quest for the key to neurotrophism. Life (Basel). 2025;15(3): 391.
24. Rosso G, Peracchia S, Rizzo Pesci N, et al. Third-generation antipsychotics as augmentation in treatment-resistant obsessive-compulsive disorder: a narrative review of efficacy and tolerability. Biomedicines. 2026;14(1):179.
25. Smith CM, Augustine MS, Dorrough J, et al. Xanomeline-trospium (CobenfyTM) for schizophrenia: a review of the literature. Clin Psychopharmacol Neurosci. 2025;23(1):2-14.
26. Kaul I, Sawchak S, Walling DP, et al. Efficacy and safety of xanomeline-trospium chloride in schizophrenia: a randomized clinical trial. JAMA Psychiatry. 2024;81(8):749-756.
27. GoodRx. 6 Popular Medication Reminder Apps Available for Apple and Android. Available at https://www.goodrx.com/healthcare-access/digital-health/medication-reminder-apps?srsltid=AfmBOoozwZH19O36wXk_QyJH0c1l3w9Od_PxNkAt0zAM4YQIrYnO1j34. Last accessed July 27, 2026.
28. Muench J, Hamer AM. Adverse effects of antipsychotic medications. Am Fam Physician. 2010;81(5):617-622.
29. Kandra K. Aripiprazole- and lurasidone-induced akathisia: a case report and literature review. Cureus. 2025;17(9):e92704.
30. National Library of Medicine. Stat Pearls: Dystonic Reactions. Available at https://www.ncbi.nlm.nih.gov/books/NBK531466. Last accessed August 14, 2026.
31. Berman BD. Neuroleptic malignant syndrome: a review for neurohospitalists. Neurohospitalist. 2011;1(1):41-47.
32. Haddad PM, Dursun SM. Neurological complications of psychiatric drugs: clinical features and management. Hum Psychopharmacol. 2008;23 Suppl 1:15-26.
33. Ray WA, Chung CP, Murray KT, Hall K, Stein CM. Atypical antipsychotic drugs and the risk of sudden cardiac death. N Engl J Med. 2009;360(3):225-235.
34. National Alliance on Mental Illness. Tardive Dyskinesia. Available at https://www.nami.org/treatments-and-approaches/mental-health-medications/tardive-dyskinesia/. Last accessed August 5, 2026.
35. Jankovic J. Dopamine depleters in the treatment of hyperkinetic movement disorders. Expert Opin Pharmacother. 2016;17(18):2461-2470.
36. Touma KTB, Scarff JR. Valbenazine and deutetrabenazine for tardive dyskinesia. Innov Clin Neurosci. 2018;15(5-6):13-16.
37. U.S. Food and Drug Administration. FDA Removes Risk Evaluation and Mitigation Strategy (REMS) Program for the Antipsychotic Drug Clozapine. Available at https://www.fda.gov/drugs/drug-safety-communications/fda-removes-risk-evaluation-and-mitigation-strategy-rems-program-antipsychotic-drug-clozapine. Last accessed August 5, 2026.
39. Greenhalgh N. Schizophrenia Case Studies: Putting Theory into Practice. Available at https://pharmaceutical-journal.com/article/ld/schizophrenia-case-studies-putting-theory-into-practice. Last accessed August 10, 2026.
40. Clinical Resource: Drug Interactions: Cytochrome P450 (CYP), P-glycoprotein, and More. Pharmacist's Letter/Prescriber's Letter. May 2024.
41. Product Information for Milsaperidone (Bysanti). Vanda Pharmaceuticals Inc. Washington, D.C. 20037. February 2026.
42. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353(12):1209-1223.
43. Huhn M, Nikolakopoulou A, Schneider-Thoma J, Krause M, et al. Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. Lancet. 2019;394(10202):939-951.
44. Bobo WV. The diagnosis and management of bipolar I and II disorders: clinical practice update. Mayo Clin Proc. 2017;92(10):1532-1551.
45. Shah N, Grover S, Rao GP. Clinical practice guidelines for management of bipolar disorder. Indian J Psychiatry. 2017;59(Suppl 1):S51-S66.
46. Magellan Health Services. Prescribing Guidelines for Atypical Antipsychotics. Available at https://www.magellanprovider.com/media/11780/guidelines_atypicalantipsychotics.pdf. Last accessed August 5, 2026.
47. Bostwick JR, Murphy LR. Metabolic Monitoring of Antipsychotic Medications: What Psychiatrists Need to Know. Available at https://www.psychiatrictimes.com/view/realities-childhood-schizophrenia. Last accessed August 5, 2026.
48. DeJongh BM. Clinical pearls for the monitoring and treatment of antipsychotic induced metabolic syndrome. Ment Health Clin. 2021;11(6):311-319.
49. Diabetes Canada Clinical Practice Guidelines Expert Committee. Diabetes Canada 2018 clinical practice guidelines for the prevention and management of diabetes in Canada. Can J Diabetes. 2018;42(Suppl 1):S1-S325.
50. Aubry R, Hastings T, Morgan M, et al. Guideline concordant screening and monitoring of extrapyramidal symptoms in patients prescribed antipsychotic medication: a protocol for a systematic literature review and narrative synthesis. BMJ Open. 2024;14(9):e087632.
51. Maher AR, Maglione M, Bagley S, et al. Efficacy and comparative effectiveness of atypical antipsychotic medications for off-label uses in adults: a systematic review and meta-analysis. JAMA. 2011 Sep 28;306(12):1359-69. Erratum in: JAMA. 2012 Jan 11;307(2):147.
52. Katzman MA, Bleau P, Blier P, et al. Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders. BMC Psychiatry. 2014;14 Suppl 1(Suppl 1):S1.
53. Hershenberg R, Gros DF, Brawman-Mintzer O. Role of atypical antipsychotics in the treatment of generalized anxiety disorder. CNS Drugs. 2014;28(6):519-533.
54. Reus VI, Fochtmann LJ, Eyler AE, et al. The American Psychiatric Association practice guideline on the use of antipsychotics to treat agitation or psychosis in patients with dementia. Am J Psychiatry. 2016;173(5):543-546.
55. Canadian Geriatrics Society. Antipsychotic Use in Older Adults with Dementia and Behavioural and Psychological Symptoms of Dementia (BPSD). Available at https://static1.squarespace.com/static/63599251a953f80dd1922762/t/68dfe570990769326adef6d2/1759503728391/ANTIPS.pdf. Last accessed August 5, 2026.
56. Kennedy SH, Lam RW, McIntyre RS, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder: section 3. pharmacological treatments. Can J Psychiatry. 2016;61(9):540-560. Erratum in: Can J Psychiatry. 2017;62(5):356.
57. Hernandez Sanchez JM, Molina Lopez MF, Cancino Botello MC, et al. Atypical antipsychotics use in eating disorders: review. European Psychiatry. 2016;33:S429.
58. American Family Physician. Antipsychotics for Obsessive-Compulsive Disorder. Available at https://www.aafp.org/afp/2025/1100/letter-antipsychotics-obsessive-compulsive-disorder#afp20251100p472a-b2. Last accessed August 5, 2026.
59. U.S. Department of Veterans Affairs. VA/DoD Clinical Practice Guideline for the Management of Posttraumatic Stress Disorder and Acute Stress Disorder, Version 4.0. Available at https://www.healthquality.va.gov/HEALTHQUALITY/guidelines/MH/ptsd/VA-DoD-CPG-PTSD-Full-CPG-Edited-111624-V5-81825.pdf. Last accessed August 10, 2026.
60. Krystal JH, Rosenheck RA, Cramer JA, et al. Adjunctive risperidone treatment for antidepressant-resistant symptoms of chronic military service-related PTSD: a randomized trial. JAMA. 2011;306(5):493-502.
61. U.S. Department of Veterans Affairs. PTSD: National Center for PTSD. Available at https://www.ptsd.va.gov/understand_tx/meds_for_ptsd.asp. Last accessed August 10, 2026.
62. Kleber HD, Weiss RD, Anton RF, et al. Practice Guideline for the Treatment of Patients with Substance Use Disorders, Second Edition. Available at https://psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/guidelines/substanceuse.pdf. Last accessed August 10, 2026.
63. U.S. Department of Veterans Affairs. VA/DoD Clinical Practice Guideline for the Management of Substance Use Disorders. Version 5.0. Available at https://www.healthquality.va.gov/HEALTHQUALITY/guidelines/MH/sud/VA-DoD-SUD-CPG_Final_for-508_v3.pdf. Last accessed August 10, 2026.
64. Guzman F. Long-Acting Injectable Antipsychotics: A Practical Guide for Prescribers. Available at https://psychopharmacologyinstitute.com/publication/long-acting-injectable-antipsychotics-a-practical-guide-for-prescribers-2201. Last accessed August 10, 2026.
- Back to Course Home
- Participation Instructions
- Review the course material online or in print.
- Complete the course evaluation.
- Review your Transcript to view and print your Certificate of Completion. Your date of completion will be the date (Pacific Time) the course was electronically submitted for credit, with no exceptions. Partial credit is not available.